TY  - THES
AU  - Ignjatović, Jelisaveta
PY  - 2023
UR  - https://eteze.bg.ac.rs/application/showtheses?thesesId=9344
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:31764/bdef:Content/download
UR  - https://plus.cobiss.net/cobiss/sr/sr/bib/113522953
UR  - https://nardus.mpn.gov.rs/handle/123456789/21918
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5320
AB  - Inhalacioni put primene lekova pokazuje brojne prednosti, no broj registrovanih preparata za ovaj put primene je relativno ograničen u odnosu na ostale vrste preparata. Dodatno, svi do sada registrovani preparati za inhalaciju predstavljaju preparate sa trenutnim oslobađanjem lekovite supstance. Poslednjih godina se intenzivno radi na razvoju preparata za inhalaciju sa modifikovanim oslobađanjem lekovite supstance, koji bi mogli da doprinesu povećanju komplijanse pacijenata i efikasnosti terapije. U skladu sa tim, cilj ove disertacije je razvoj formulacije čvrstih lipidnih mikročestica u obliku praškova za inhalaciju, odgovarajućih aerodinamičkih karakteristika i sa modifikovanim oslobađanjem lekovite supstance, kao i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različih biofarmaceutskih svojstava, salbutamol-sulfata i budesonida.Metodom emulgovanja na povišenoj temperaturi, u kombinaciji sa sušenjem raspršivanjem, izrađeni su praškovi za inhalaciju u obliku čvrstih lipidnih mikročestica, koji su pokazali odgovarajuće aerodinamičke karakteristike i modifikovanu (produženu) brzinu oslobađanja salbutamol-sulfata u odnosu na prašak čistog salbutamol-sulfata. Rezultati sprovedenih ispitivanja su ukazali na značaj primene in silico modela zasnovanih na računarskoj dinamici fluida i čestica u razvoju praškova za inhalaciju, jer su na ovaj način određene karakteristike ispitivanih formulacija koje nije moguće utvrditi in vitro metodama.Fiziološki-zasnovano farmakokinetičko (PBPK) modelovanje pokazalo je da bi se inhalacionom primenom mukoadhezivnog praška sa modifikovanim oslobađanjem budesonida postiglo sporije rastvaranje i produžena apsorpcija budesonida. Takođe, rezultati PBPK modelovanja ukazali su na to da bi inhalacionom primenom praškova čvrstih lipidnih mikročestica mogla da se produži apsorpcija salbutamola u plućima. Pri tome je predviđeno da se, nakon primene praškova čvrstih lipidnih mikročestica, veći procenat salbutamola apsorbuje putem pluća, a manji iz gastrointestinalnog trakta, u odnosu na registrovani preparat sa trenutnim oslobađanjem lekovite supstance. Dobijeni rezultati ukazuju na to da bi inhalaciona primena praškova čvrstih lipidnih mikročestica potencijalno mogla obezbediti veću efikasnost i bezbednost inhalacione terapije.
AB  - Pulmonary drug delivery has many advantages, but the number of marketed inhalation products is still limited, in comparison to the other types of drug products. In addition, all currently marketed inhalation medicines represent immediate release drug products. The development of modified-release inhalation products has received widespread attention over the last few years, since they can improve patient compliance and treatment efficacy. Therefore, the aim of this dissertation was to develop solid lipid microparticles as dry powders for inhalation (DPIs) with adequate aerodynamic characteristics and modified drug release, as well as in vitro/in silico characterization of modified-release DPIs with drugs of different biopharmaceutical properties, salbutamol-sulphate and budesonide.DPIs comprised of solid lipid microparticles were successfully formulated and prepared using the melt emulsification process coupled with spray drying. The obtained formulations exhibited suitable aerodynamic characteristics and modified (prolonged) drug release in comparison to the raw salbutamol-sulphate powder. The results of in silico characterization studies highlighted the importance of computational fluid and particle dynamics models in the DPI development, considering that these models enabled the assessment of certain DPI characteristics which cannot be determined using in vitro methods.Physiologically-based pharmacokinetic (PBPK) modeling indicated that inhalation administration of mucoadhesive modified-release DPI may provide prolonged budesonide dissolution and absorption in the lungs. Also, PBPK modeling results implied that inhalation of DPI comprised of solid lipid microparticles may lead to prolonged salbutamol pulmonary absorption. In addition, the model predicted increased salbutamol absorption in the lungs, together with decreased absorption in the gastrointestinal tract, following inhalation administration of solid lipid microparticles, in comparison to the marketed immediate release drug product. The obtained results implied that inhalation administration of DPIs containing solid lipid microparticles could potentially improve therapeutic efficacy and safety of inhaled drugs.
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Razvoj formulacije i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različitih biofarmaceutskih svojstava
UR  - https://hdl.handle.net/21.15107/rcub_nardus_21918
ER  - 

@phdthesis{
author = "Ignjatović, Jelisaveta",
year = "2023",
abstract = "Inhalacioni put primene lekova pokazuje brojne prednosti, no broj registrovanih preparata za ovaj put primene je relativno ograničen u odnosu na ostale vrste preparata. Dodatno, svi do sada registrovani preparati za inhalaciju predstavljaju preparate sa trenutnim oslobađanjem lekovite supstance. Poslednjih godina se intenzivno radi na razvoju preparata za inhalaciju sa modifikovanim oslobađanjem lekovite supstance, koji bi mogli da doprinesu povećanju komplijanse pacijenata i efikasnosti terapije. U skladu sa tim, cilj ove disertacije je razvoj formulacije čvrstih lipidnih mikročestica u obliku praškova za inhalaciju, odgovarajućih aerodinamičkih karakteristika i sa modifikovanim oslobađanjem lekovite supstance, kao i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različih biofarmaceutskih svojstava, salbutamol-sulfata i budesonida.Metodom emulgovanja na povišenoj temperaturi, u kombinaciji sa sušenjem raspršivanjem, izrađeni su praškovi za inhalaciju u obliku čvrstih lipidnih mikročestica, koji su pokazali odgovarajuće aerodinamičke karakteristike i modifikovanu (produženu) brzinu oslobađanja salbutamol-sulfata u odnosu na prašak čistog salbutamol-sulfata. Rezultati sprovedenih ispitivanja su ukazali na značaj primene in silico modela zasnovanih na računarskoj dinamici fluida i čestica u razvoju praškova za inhalaciju, jer su na ovaj način određene karakteristike ispitivanih formulacija koje nije moguće utvrditi in vitro metodama.Fiziološki-zasnovano farmakokinetičko (PBPK) modelovanje pokazalo je da bi se inhalacionom primenom mukoadhezivnog praška sa modifikovanim oslobađanjem budesonida postiglo sporije rastvaranje i produžena apsorpcija budesonida. Takođe, rezultati PBPK modelovanja ukazali su na to da bi inhalacionom primenom praškova čvrstih lipidnih mikročestica mogla da se produži apsorpcija salbutamola u plućima. Pri tome je predviđeno da se, nakon primene praškova čvrstih lipidnih mikročestica, veći procenat salbutamola apsorbuje putem pluća, a manji iz gastrointestinalnog trakta, u odnosu na registrovani preparat sa trenutnim oslobađanjem lekovite supstance. Dobijeni rezultati ukazuju na to da bi inhalaciona primena praškova čvrstih lipidnih mikročestica potencijalno mogla obezbediti veću efikasnost i bezbednost inhalacione terapije., Pulmonary drug delivery has many advantages, but the number of marketed inhalation products is still limited, in comparison to the other types of drug products. In addition, all currently marketed inhalation medicines represent immediate release drug products. The development of modified-release inhalation products has received widespread attention over the last few years, since they can improve patient compliance and treatment efficacy. Therefore, the aim of this dissertation was to develop solid lipid microparticles as dry powders for inhalation (DPIs) with adequate aerodynamic characteristics and modified drug release, as well as in vitro/in silico characterization of modified-release DPIs with drugs of different biopharmaceutical properties, salbutamol-sulphate and budesonide.DPIs comprised of solid lipid microparticles were successfully formulated and prepared using the melt emulsification process coupled with spray drying. The obtained formulations exhibited suitable aerodynamic characteristics and modified (prolonged) drug release in comparison to the raw salbutamol-sulphate powder. The results of in silico characterization studies highlighted the importance of computational fluid and particle dynamics models in the DPI development, considering that these models enabled the assessment of certain DPI characteristics which cannot be determined using in vitro methods.Physiologically-based pharmacokinetic (PBPK) modeling indicated that inhalation administration of mucoadhesive modified-release DPI may provide prolonged budesonide dissolution and absorption in the lungs. Also, PBPK modeling results implied that inhalation of DPI comprised of solid lipid microparticles may lead to prolonged salbutamol pulmonary absorption. In addition, the model predicted increased salbutamol absorption in the lungs, together with decreased absorption in the gastrointestinal tract, following inhalation administration of solid lipid microparticles, in comparison to the marketed immediate release drug product. The obtained results implied that inhalation administration of DPIs containing solid lipid microparticles could potentially improve therapeutic efficacy and safety of inhaled drugs.",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Razvoj formulacije i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različitih biofarmaceutskih svojstava",
url = "https://hdl.handle.net/21.15107/rcub_nardus_21918"
}

Ignjatović, J.. (2023). Razvoj formulacije i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različitih biofarmaceutskih svojstava. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_21918

Ignjatović J. Razvoj formulacije i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različitih biofarmaceutskih svojstava. in Универзитет у Београду. 2023;.
https://hdl.handle.net/21.15107/rcub_nardus_21918 .

Ignjatović, Jelisaveta, "Razvoj formulacije i in vitro/in silico karakterizacija praškova za inhalaciju sa modifikovanim oslobađanjem lekovitih supstanci različitih biofarmaceutskih svojstava" in Универзитет у Београду (2023),
https://hdl.handle.net/21.15107/rcub_nardus_21918 .

TY  - JOUR
AU  - Shi, Changzhi
AU  - Ignjatović, Jelisaveta
AU  - Wang, Junwei
AU  - Guo, Yi
AU  - Zhang, Li
AU  - Cvijić, Sandra
AU  - Cun, Dongmei
AU  - Yang, Mingshi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4291
AB  - Respiratory antibiotics have been proven clinically beneficial for the treatment of severe lung infections such as Pseudomonas aeruginosa. Maintaining a high local concentration of inhaled antibiotics for an extended time in the lung is crucial to ensure an adequate antimicrobial efficiency. In this study, we aim to investigate whether an extended exposure of ciprofloxacin (CIP), a model fluoroquinolone drug, in the lung epithelial lining fluid (ELF) could be achieved via a controlled-release formulation strategy. CIP solutions were intratracheally instilled to the rat lungs at 3 different rates, i.e., T0h (fast), T2h (medium), and T4h (slow), to mimic different release profiles of inhaled CIP formulations in the lung. Subsequently, the concentration-time profiles of CIP in the plasma and the lung ELF were obtained, respectively, to determine topical exposure index (ELF-Plasma AUC Ratio, EPR). The in silico PBPK model, validated based on the in vivo data, was used to identify the key factors that influence the disposition of CIP in the plasma and lungs. The medium and slow rates groups exhibited much higher EPR than that fast instillation group. The ELF AUC of the medium and slow instillation groups were about 200 times higher than their plasma AUC. In contrast, the ELF AUC of the fast instillation group was only about 20 times higher than the plasma AUC. The generated whole-body PBPK rat model, validated by comparison with the in vivo data, revealed that drug pulmonary absorption rate was the key factor that determined pulmonary absorption of CIP. This study suggests that controlled CIP release from inhaled formulations may extend the exposure of CIP in the ELF post pulmonary administration. It also demonstrates that combining the proposed intratracheal installation model and in silico PBPK model is a useful approach to identify the key factors that influence the absorption and disposition of inhaled medicine.
PB  - Elsevier B.V.
T2  - Chinese Chemical Letters
T1  - Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies
VL  - 34
IS  - 1
DO  - 10.1016/j.cclet.2022.04.061
ER  - 

@article{
author = "Shi, Changzhi and Ignjatović, Jelisaveta and Wang, Junwei and Guo, Yi and Zhang, Li and Cvijić, Sandra and Cun, Dongmei and Yang, Mingshi",
year = "2023",
abstract = "Respiratory antibiotics have been proven clinically beneficial for the treatment of severe lung infections such as Pseudomonas aeruginosa. Maintaining a high local concentration of inhaled antibiotics for an extended time in the lung is crucial to ensure an adequate antimicrobial efficiency. In this study, we aim to investigate whether an extended exposure of ciprofloxacin (CIP), a model fluoroquinolone drug, in the lung epithelial lining fluid (ELF) could be achieved via a controlled-release formulation strategy. CIP solutions were intratracheally instilled to the rat lungs at 3 different rates, i.e., T0h (fast), T2h (medium), and T4h (slow), to mimic different release profiles of inhaled CIP formulations in the lung. Subsequently, the concentration-time profiles of CIP in the plasma and the lung ELF were obtained, respectively, to determine topical exposure index (ELF-Plasma AUC Ratio, EPR). The in silico PBPK model, validated based on the in vivo data, was used to identify the key factors that influence the disposition of CIP in the plasma and lungs. The medium and slow rates groups exhibited much higher EPR than that fast instillation group. The ELF AUC of the medium and slow instillation groups were about 200 times higher than their plasma AUC. In contrast, the ELF AUC of the fast instillation group was only about 20 times higher than the plasma AUC. The generated whole-body PBPK rat model, validated by comparison with the in vivo data, revealed that drug pulmonary absorption rate was the key factor that determined pulmonary absorption of CIP. This study suggests that controlled CIP release from inhaled formulations may extend the exposure of CIP in the ELF post pulmonary administration. It also demonstrates that combining the proposed intratracheal installation model and in silico PBPK model is a useful approach to identify the key factors that influence the absorption and disposition of inhaled medicine.",
publisher = "Elsevier B.V.",
journal = "Chinese Chemical Letters",
title = "Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies",
volume = "34",
number = "1",
doi = "10.1016/j.cclet.2022.04.061"
}

Shi, C., Ignjatović, J., Wang, J., Guo, Y., Zhang, L., Cvijić, S., Cun, D.,& Yang, M.. (2023). Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. in Chinese Chemical Letters
Elsevier B.V.., 34(1).
https://doi.org/10.1016/j.cclet.2022.04.061

Shi C, Ignjatović J, Wang J, Guo Y, Zhang L, Cvijić S, Cun D, Yang M. Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. in Chinese Chemical Letters. 2023;34(1).
doi:10.1016/j.cclet.2022.04.061 .

Shi, Changzhi, Ignjatović, Jelisaveta, Wang, Junwei, Guo, Yi, Zhang, Li, Cvijić, Sandra, Cun, Dongmei, Yang, Mingshi, "Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies" in Chinese Chemical Letters, 34, no. 1 (2023),
https://doi.org/10.1016/j.cclet.2022.04.061 . .

TY  - JOUR
AU  - Šušteršič, Tijana
AU  - Bodić, Aleksandar
AU  - Ignjatović, Jelisaveta
AU  - Cvijić, Sandra
AU  - Ibrić, Svetlana
AU  - Filipović, Nenad
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4367
AB  - The development of novel dry powders for dry powder inhalers (DPIs) requires the in vitro assessment of DPI aerodynamic performance. As a potential complementary method, in silico numerical simulations can provide additional information about the mechanisms that guide the particles and their behavior inside DPIs. The aim of this study was to apply computational fluid dynamics (CFDs) coupled with a discrete phase model (DPM) to describe the forces and particle trajectories inside the RS01® as a model DPI device. The methodology included standard fluid flow equations but also additional equations for the particle sticking mechanism, as well as particle behavior after contacting the DPI wall surface, including the particle detachment process. The results show that the coefficient of restitution between the particle and the impact surface does not have a high impact on the results, meaning that all tested combinations gave similar output efficiencies and particle behaviors. No sliding or rolling mechanisms were observed for the particle detachment process, meaning that simple bouncing off or deposition particle behavior is present inside DPIs. The developed methodology can serve as a basis for the additional understanding of the particles’ behavior inside DPIs, which is not possible using only in vitro experiments; this implies the possibility of increasing the efficiency of DPIs.
PB  - MDPI
T2  - Pharmaceutics
T1  - Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler
VL  - 14
IS  - 12
DO  - 10.3390/pharmaceutics14122591
ER  - 

@article{
author = "Šušteršič, Tijana and Bodić, Aleksandar and Ignjatović, Jelisaveta and Cvijić, Sandra and Ibrić, Svetlana and Filipović, Nenad",
year = "2022",
abstract = "The development of novel dry powders for dry powder inhalers (DPIs) requires the in vitro assessment of DPI aerodynamic performance. As a potential complementary method, in silico numerical simulations can provide additional information about the mechanisms that guide the particles and their behavior inside DPIs. The aim of this study was to apply computational fluid dynamics (CFDs) coupled with a discrete phase model (DPM) to describe the forces and particle trajectories inside the RS01® as a model DPI device. The methodology included standard fluid flow equations but also additional equations for the particle sticking mechanism, as well as particle behavior after contacting the DPI wall surface, including the particle detachment process. The results show that the coefficient of restitution between the particle and the impact surface does not have a high impact on the results, meaning that all tested combinations gave similar output efficiencies and particle behaviors. No sliding or rolling mechanisms were observed for the particle detachment process, meaning that simple bouncing off or deposition particle behavior is present inside DPIs. The developed methodology can serve as a basis for the additional understanding of the particles’ behavior inside DPIs, which is not possible using only in vitro experiments; this implies the possibility of increasing the efficiency of DPIs.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler",
volume = "14",
number = "12",
doi = "10.3390/pharmaceutics14122591"
}

Šušteršič, T., Bodić, A., Ignjatović, J., Cvijić, S., Ibrić, S.,& Filipović, N.. (2022). Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler. in Pharmaceutics
MDPI., 14(12).
https://doi.org/10.3390/pharmaceutics14122591

Šušteršič T, Bodić A, Ignjatović J, Cvijić S, Ibrić S, Filipović N. Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler. in Pharmaceutics. 2022;14(12).
doi:10.3390/pharmaceutics14122591 .

Šušteršič, Tijana, Bodić, Aleksandar, Ignjatović, Jelisaveta, Cvijić, Sandra, Ibrić, Svetlana, Filipović, Nenad, "Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler" in Pharmaceutics, 14, no. 12 (2022),
https://doi.org/10.3390/pharmaceutics14122591 . .

TY  - CONF
AU  - Đoković, Nemanja
AU  - Ružić, Dušan
AU  - Đikić, Teodora
AU  - Cvijić, Sandra
AU  - Ignjatović, Jelisaveta
AU  - Ibrić, Svetlana
AU  - Baralić, Katarina
AU  - Buha-Đorđević, Aleksandra
AU  - Ćurčić, Marijana
AU  - Đukić-Ćosić, Danijela
AU  - Nikolić, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4896
PB  - Hellenic Society of Medicinal Chemistry
C3  - 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium
T1  - Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4896
ER  - 

@conference{
author = "Đoković, Nemanja and Ružić, Dušan and Đikić, Teodora and Cvijić, Sandra and Ignjatović, Jelisaveta and Ibrić, Svetlana and Baralić, Katarina and Buha-Đorđević, Aleksandra and Ćurčić, Marijana and Đukić-Ćosić, Danijela and Nikolić, Katarina",
year = "2021",
publisher = "Hellenic Society of Medicinal Chemistry",
journal = "18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium",
title = "Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4896"
}

Đoković, N., Ružić, D., Đikić, T., Cvijić, S., Ignjatović, J., Ibrić, S., Baralić, K., Buha-Đorđević, A., Ćurčić, M., Đukić-Ćosić, D.,& Nikolić, K.. (2021). Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach. in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium
Hellenic Society of Medicinal Chemistry..
https://hdl.handle.net/21.15107/rcub_farfar_4896

Đoković N, Ružić D, Đikić T, Cvijić S, Ignjatović J, Ibrić S, Baralić K, Buha-Đorđević A, Ćurčić M, Đukić-Ćosić D, Nikolić K. Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach. in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_4896 .

Đoković, Nemanja, Ružić, Dušan, Đikić, Teodora, Cvijić, Sandra, Ignjatović, Jelisaveta, Ibrić, Svetlana, Baralić, Katarina, Buha-Đorđević, Aleksandra, Ćurčić, Marijana, Đukić-Ćosić, Danijela, Nikolić, Katarina, "Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach" in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium (2021),
https://hdl.handle.net/21.15107/rcub_farfar_4896 .

TY  - JOUR
AU  - Ignjatović, Jelisaveta
AU  - Šušteršič, Tijana
AU  - Bodić, Aleksandar
AU  - Cvijić, Sandra
AU  - Ðuriš, Jelena
AU  - Rossi, Alessandra
AU  - Dobričić, Vladimir
AU  - Ibrić, Svetlana
AU  - Filipović, Nenad
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3993
AB  - In vitro assessment of dry powders for inhalation (DPIs) aerodynamic performance is an inevitable test in DPI development. However, contemporary trends in drug development also implicate the use of in silico methods, e.g., computational fluid dynamics (CFD) coupled with discrete phase modeling (DPM). The aim of this study was to compare the designed CFD-DPM outcomes with the results of three in vitro methods for aerodynamic assessment of solid lipid microparticle DPIs. The model was able to simulate particle-to-wall sticking and estimate fractions of particles that stick or bounce off the inhaler’s wall; however, we observed notable differences between the in silico and in vitro results. The predicted emitted fractions (EFs) were comparable to the in vitro determined EFs, whereas the predicted fine particle fractions (FPFs) were generally lower than the corresponding in vitro values. In addition, CFD-DPM predicted higher mass median aerodynamic diameter (MMAD) in comparison to the in vitro values. The outcomes of different in vitro methods also diverged, implying that these methods are not interchangeable. Overall, our results support the utility of CFD-DPM in the DPI development, but highlight the need for additional improvements in these models to capture all the key processes influencing aerodynamic performance of specific DPIs.
PB  - MDPI
T2  - Pharmaceutics
T1  - Comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation
VL  - 13
IS  - 11
DO  - 10.3390/pharmaceutics13111831
ER  - 

@article{
author = "Ignjatović, Jelisaveta and Šušteršič, Tijana and Bodić, Aleksandar and Cvijić, Sandra and Ðuriš, Jelena and Rossi, Alessandra and Dobričić, Vladimir and Ibrić, Svetlana and Filipović, Nenad",
year = "2021",
abstract = "In vitro assessment of dry powders for inhalation (DPIs) aerodynamic performance is an inevitable test in DPI development. However, contemporary trends in drug development also implicate the use of in silico methods, e.g., computational fluid dynamics (CFD) coupled with discrete phase modeling (DPM). The aim of this study was to compare the designed CFD-DPM outcomes with the results of three in vitro methods for aerodynamic assessment of solid lipid microparticle DPIs. The model was able to simulate particle-to-wall sticking and estimate fractions of particles that stick or bounce off the inhaler’s wall; however, we observed notable differences between the in silico and in vitro results. The predicted emitted fractions (EFs) were comparable to the in vitro determined EFs, whereas the predicted fine particle fractions (FPFs) were generally lower than the corresponding in vitro values. In addition, CFD-DPM predicted higher mass median aerodynamic diameter (MMAD) in comparison to the in vitro values. The outcomes of different in vitro methods also diverged, implying that these methods are not interchangeable. Overall, our results support the utility of CFD-DPM in the DPI development, but highlight the need for additional improvements in these models to capture all the key processes influencing aerodynamic performance of specific DPIs.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation",
volume = "13",
number = "11",
doi = "10.3390/pharmaceutics13111831"
}

Ignjatović, J., Šušteršič, T., Bodić, A., Cvijić, S., Ðuriš, J., Rossi, A., Dobričić, V., Ibrić, S.,& Filipović, N.. (2021). Comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation. in Pharmaceutics
MDPI., 13(11).
https://doi.org/10.3390/pharmaceutics13111831

Ignjatović J, Šušteršič T, Bodić A, Cvijić S, Ðuriš J, Rossi A, Dobričić V, Ibrić S, Filipović N. Comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation. in Pharmaceutics. 2021;13(11).
doi:10.3390/pharmaceutics13111831 .

Ignjatović, Jelisaveta, Šušteršič, Tijana, Bodić, Aleksandar, Cvijić, Sandra, Ðuriš, Jelena, Rossi, Alessandra, Dobričić, Vladimir, Ibrić, Svetlana, Filipović, Nenad, "Comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation" in Pharmaceutics, 13, no. 11 (2021),
https://doi.org/10.3390/pharmaceutics13111831 . .

TY  - JOUR
AU  - Cvijić, Sandra
AU  - Ignjatović, Jelisaveta
AU  - Parojčić, Jelena
AU  - Ibrić, Svetlana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3959
AB  - Computer-based (in silico) modeling & simulation tools have been embraced in different
fields of pharmaceutics for a variety of applications. Among these, physiologically-based
pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a particularly useful
tool in formulation development. PBPK/PBBM facilitated strategies have been increasingly
evaluated over the past few years, as demonstrated by several reports from the pharmaceutical
industry, and a number of research and review papers on this subject. Also, the leading regulatory
authorities have recently issued guidance on the use of PBPK modeling in formulation design. In
silico PBPK models can comprise different dosing routes (oral, intraoral, parenteral, inhalation,
ocular, dermal etc.), although the majority of published examples refer to modeling of oral drugs
performance. In order to facilitate the use of PBPK modeling tools, a couple of companies have
launched commercially available software such as GastroPlus™, Simcyp™ PBPK Simulator and
PK-Sim®. This paper highlights various application fields of PBPK/PBBM modeling, along with
the basic principles, advantages and limitations of this approach, and provides relevant examples
to demonstrate the practical utility of modeling & simulation tools in different stages of
formulation development.
AB  - Računarski podržano (in silico) modelovanje se danas koristi u različitim oblastima farmaceutskih nauka, sa širokom paletom primene. Kao jedan od in silico alata, fiziološki zasnovano farmakokinetičko/biofarmaceutsko modelovanje (PBPK/PBBM) se pokazalo posebno korisnim u razvoju farmaceutskih preparata. Strategije zasnovane na PBPK/PBBM modelovanju se poslednjih godina sve više razmatraju, što se vidi iz izveštaja farmaceutskih kompanija i velikog broja publikovanih istraživačkih i revijalnih radova na ovu temu. Takođe, vodeće regulatorne agencije su nedavno izdale vodiče koji se odnose na primenu PBPK modelovanja u razvoju farmaceutskih preparata. In silico PBPK modelovanje je primenjivo za različite puteve primene leka (peroralni, (intra)oralni, parenteralni, inhalacioni, okularni, dermalni itd), mada se najveći broj primera iz literature odnosi na modelovanje bioperformansi peroralno primenjenih lekova. Kako bi olakšale primenu PBPK modelovanja, nekoliko kompanija je razvilo komercijalno dostupne programske pakete, kao što su GastroPlus™, Simcyp™ PBPK Simulator i PK-Sim®. U ovom radu su istaknute različite mogućnosti primene PBPK/PBBM modelovanja, uključujući osnovne principe, prednosti i ograničenja. Takođe, prikazani su odgovarajući primeri koji opisuju praktičnu primenu modelovanja i simulacija u različitim fazama razvoja leka.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development
T1  - Uloga fiziološki-zasnovanog farmakokinetičkog/biofarmaceutskog modelovanja u razvoju farmaceutskih preparata
VL  - 71
IS  - 4
SP  - 318
EP  - 335
DO  - 10.5937/arhfarm71-32479
ER  - 

@article{
author = "Cvijić, Sandra and Ignjatović, Jelisaveta and Parojčić, Jelena and Ibrić, Svetlana",
year = "2021",
abstract = "Computer-based (in silico) modeling & simulation tools have been embraced in different
fields of pharmaceutics for a variety of applications. Among these, physiologically-based
pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a particularly useful
tool in formulation development. PBPK/PBBM facilitated strategies have been increasingly
evaluated over the past few years, as demonstrated by several reports from the pharmaceutical
industry, and a number of research and review papers on this subject. Also, the leading regulatory
authorities have recently issued guidance on the use of PBPK modeling in formulation design. In
silico PBPK models can comprise different dosing routes (oral, intraoral, parenteral, inhalation,
ocular, dermal etc.), although the majority of published examples refer to modeling of oral drugs
performance. In order to facilitate the use of PBPK modeling tools, a couple of companies have
launched commercially available software such as GastroPlus™, Simcyp™ PBPK Simulator and
PK-Sim®. This paper highlights various application fields of PBPK/PBBM modeling, along with
the basic principles, advantages and limitations of this approach, and provides relevant examples
to demonstrate the practical utility of modeling & simulation tools in different stages of
formulation development., Računarski podržano (in silico) modelovanje se danas koristi u različitim oblastima farmaceutskih nauka, sa širokom paletom primene. Kao jedan od in silico alata, fiziološki zasnovano farmakokinetičko/biofarmaceutsko modelovanje (PBPK/PBBM) se pokazalo posebno korisnim u razvoju farmaceutskih preparata. Strategije zasnovane na PBPK/PBBM modelovanju se poslednjih godina sve više razmatraju, što se vidi iz izveštaja farmaceutskih kompanija i velikog broja publikovanih istraživačkih i revijalnih radova na ovu temu. Takođe, vodeće regulatorne agencije su nedavno izdale vodiče koji se odnose na primenu PBPK modelovanja u razvoju farmaceutskih preparata. In silico PBPK modelovanje je primenjivo za različite puteve primene leka (peroralni, (intra)oralni, parenteralni, inhalacioni, okularni, dermalni itd), mada se najveći broj primera iz literature odnosi na modelovanje bioperformansi peroralno primenjenih lekova. Kako bi olakšale primenu PBPK modelovanja, nekoliko kompanija je razvilo komercijalno dostupne programske pakete, kao što su GastroPlus™, Simcyp™ PBPK Simulator i PK-Sim®. U ovom radu su istaknute različite mogućnosti primene PBPK/PBBM modelovanja, uključujući osnovne principe, prednosti i ograničenja. Takođe, prikazani su odgovarajući primeri koji opisuju praktičnu primenu modelovanja i simulacija u različitim fazama razvoja leka.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development, Uloga fiziološki-zasnovanog farmakokinetičkog/biofarmaceutskog modelovanja u razvoju farmaceutskih preparata",
volume = "71",
number = "4",
pages = "318-335",
doi = "10.5937/arhfarm71-32479"
}

Cvijić, S., Ignjatović, J., Parojčić, J.,& Ibrić, S.. (2021). The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 71(4), 318-335.
https://doi.org/10.5937/arhfarm71-32479

Cvijić S, Ignjatović J, Parojčić J, Ibrić S. The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development. in Arhiv za farmaciju. 2021;71(4):318-335.
doi:10.5937/arhfarm71-32479 .

Cvijić, Sandra, Ignjatović, Jelisaveta, Parojčić, Jelena, Ibrić, Svetlana, "The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development" in Arhiv za farmaciju, 71, no. 4 (2021):318-335,
https://doi.org/10.5937/arhfarm71-32479 . .

TY  - JOUR
AU  - Shi, Changzhi
AU  - Ignjatović, Jelisaveta
AU  - Liu, Tingting
AU  - Han, Meihua
AU  - Cun, Dongmei
AU  - Đuriš, Jelena
AU  - Yang, Mingshi
AU  - Cvijić, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3902
AB  - This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.
PB  - Elsevier B.V.
T2  - Asian Journal of Pharmaceutical Sciences
T1  - In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
VL  - 16
IS  - 3
SP  - 350
EP  - 362
DO  - 10.1016/j.ajps.2020.12.001
ER  - 

@article{
author = "Shi, Changzhi and Ignjatović, Jelisaveta and Liu, Tingting and Han, Meihua and Cun, Dongmei and Đuriš, Jelena and Yang, Mingshi and Cvijić, Sandra",
year = "2021",
abstract = "This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.",
publisher = "Elsevier B.V.",
journal = "Asian Journal of Pharmaceutical Sciences",
title = "In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug",
volume = "16",
number = "3",
pages = "350-362",
doi = "10.1016/j.ajps.2020.12.001"
}

Shi, C., Ignjatović, J., Liu, T., Han, M., Cun, D., Đuriš, J., Yang, M.,& Cvijić, S.. (2021). In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. in Asian Journal of Pharmaceutical Sciences
Elsevier B.V.., 16(3), 350-362.
https://doi.org/10.1016/j.ajps.2020.12.001

Shi C, Ignjatović J, Liu T, Han M, Cun D, Đuriš J, Yang M, Cvijić S. In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. in Asian Journal of Pharmaceutical Sciences. 2021;16(3):350-362.
doi:10.1016/j.ajps.2020.12.001 .

Shi, Changzhi, Ignjatović, Jelisaveta, Liu, Tingting, Han, Meihua, Cun, Dongmei, Đuriš, Jelena, Yang, Mingshi, Cvijić, Sandra, "In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug" in Asian Journal of Pharmaceutical Sciences, 16, no. 3 (2021):350-362,
https://doi.org/10.1016/j.ajps.2020.12.001 . .

TY  - JOUR
AU  - Đoković, Nemanja
AU  - Ružić, Dušan
AU  - Đikić, Teodora
AU  - Cvijić, Sandra
AU  - Ignjatović, Jelisaveta
AU  - Ibrić, Svetlana
AU  - Baralić, Katarina
AU  - Buha-Đorđević, Aleksandra
AU  - Ćurčić, Marijana
AU  - Đukić-Ćosić, Danijela
AU  - Nikolić, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3830
AB  - Considering the urgent need for novel therapeutics in ongoing COVID-19 pandemic, drug repurposing approach might offer rapid solutions comparing to de novo drug design. In this study, we designed an integrative in silico drug repurposing approach for rapid selection of potential candidates against SARS-CoV-2 Main Protease (Mpro). To screen FDA-approved drugs, we implemented structure-based molecular modelling techniques, physiologically-based pharmacokinetic (PBPK) modelling of drugs disposition and data mining analysis of drug-gene-COVID-19 association. Through presented approach, we selected the most promising FDA approved drugs for further COVID-19 drug development campaigns and analysed them in context of available experimental data. To the best of our knowledge, this is unique in silico study which integrates structure-based molecular modeling of Mpro inhibitors with predictions of their tissue disposition, drug-gene-COVID-19 associations and prediction of pleiotropic effects of selected candidates.
PB  - John Wiley and Sons Inc
T2  - Molecular Informatics
T1  - An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease
VL  - 40
IS  - 5
DO  - 10.1002/minf.202000187
ER  - 

@article{
author = "Đoković, Nemanja and Ružić, Dušan and Đikić, Teodora and Cvijić, Sandra and Ignjatović, Jelisaveta and Ibrić, Svetlana and Baralić, Katarina and Buha-Đorđević, Aleksandra and Ćurčić, Marijana and Đukić-Ćosić, Danijela and Nikolić, Katarina",
year = "2021",
abstract = "Considering the urgent need for novel therapeutics in ongoing COVID-19 pandemic, drug repurposing approach might offer rapid solutions comparing to de novo drug design. In this study, we designed an integrative in silico drug repurposing approach for rapid selection of potential candidates against SARS-CoV-2 Main Protease (Mpro). To screen FDA-approved drugs, we implemented structure-based molecular modelling techniques, physiologically-based pharmacokinetic (PBPK) modelling of drugs disposition and data mining analysis of drug-gene-COVID-19 association. Through presented approach, we selected the most promising FDA approved drugs for further COVID-19 drug development campaigns and analysed them in context of available experimental data. To the best of our knowledge, this is unique in silico study which integrates structure-based molecular modeling of Mpro inhibitors with predictions of their tissue disposition, drug-gene-COVID-19 associations and prediction of pleiotropic effects of selected candidates.",
publisher = "John Wiley and Sons Inc",
journal = "Molecular Informatics",
title = "An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease",
volume = "40",
number = "5",
doi = "10.1002/minf.202000187"
}

Đoković, N., Ružić, D., Đikić, T., Cvijić, S., Ignjatović, J., Ibrić, S., Baralić, K., Buha-Đorđević, A., Ćurčić, M., Đukić-Ćosić, D.,& Nikolić, K.. (2021). An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. in Molecular Informatics
John Wiley and Sons Inc., 40(5).
https://doi.org/10.1002/minf.202000187

Đoković N, Ružić D, Đikić T, Cvijić S, Ignjatović J, Ibrić S, Baralić K, Buha-Đorđević A, Ćurčić M, Đukić-Ćosić D, Nikolić K. An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. in Molecular Informatics. 2021;40(5).
doi:10.1002/minf.202000187 .

Đoković, Nemanja, Ružić, Dušan, Đikić, Teodora, Cvijić, Sandra, Ignjatović, Jelisaveta, Ibrić, Svetlana, Baralić, Katarina, Buha-Đorđević, Aleksandra, Ćurčić, Marijana, Đukić-Ćosić, Danijela, Nikolić, Katarina, "An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease" in Molecular Informatics, 40, no. 5 (2021),
https://doi.org/10.1002/minf.202000187 . .

TY  - JOUR
AU  - Ignjatović, Jelisaveta
AU  - Đuriš, Jelena
AU  - Cvijić, Sandra
AU  - Dobričić, Vladimir
AU  - Montepietra, Agnese
AU  - Lombardi, Chiara
AU  - Ibrić, Svetlana
AU  - Rossi, Alessandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3709
AB  - The aim of this study was to optimize the parameters of the complex melt-emulsification process coupled with the spray-drying, in order to maintain the balance between solid lipid microparticles (SLMs) powders aerodynamic performance and salbutamol sulfate release rate. Quality target product profile was identified and risk management and principal component analysis were used to guide formulation development. Obtained dry powders for inhalation (DPIs) were evaluated in terms of SLMs size distribution, morphology, true density, drug content, solid state characterization studies, in vitro aerosol performance and in vitro drug release. SLMs micrographs indicated spherical, porous particles. Selected powders showed satisfactory aerosol performance with a mean mass aerodynamic diameter of around 3 μm and acceptable fine particle fraction (FPF). Addition of trehalose positively affected SLMs aerodynamic properties. The results of in vitro dissolution testing indicated that salbutamol sulfate release from the tested SLMs formulations was modified, in comparison to the raw drug release. In conclusion, SLMs in a form of DPIs were successfully developed and numerous factors that affects SLMs properties were identified in this study. Further research is required for full understanding of each factor's influence on SLMs properties and optimization of DPIs with maximized FPFs.
PB  - Elsevier B.V.
T2  - European Journal of Pharmaceutical Sciences
T1  - Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery
VL  - 156
DO  - 10.1016/j.ejps.2020.105588
ER  - 

@article{
author = "Ignjatović, Jelisaveta and Đuriš, Jelena and Cvijić, Sandra and Dobričić, Vladimir and Montepietra, Agnese and Lombardi, Chiara and Ibrić, Svetlana and Rossi, Alessandra",
year = "2021",
abstract = "The aim of this study was to optimize the parameters of the complex melt-emulsification process coupled with the spray-drying, in order to maintain the balance between solid lipid microparticles (SLMs) powders aerodynamic performance and salbutamol sulfate release rate. Quality target product profile was identified and risk management and principal component analysis were used to guide formulation development. Obtained dry powders for inhalation (DPIs) were evaluated in terms of SLMs size distribution, morphology, true density, drug content, solid state characterization studies, in vitro aerosol performance and in vitro drug release. SLMs micrographs indicated spherical, porous particles. Selected powders showed satisfactory aerosol performance with a mean mass aerodynamic diameter of around 3 μm and acceptable fine particle fraction (FPF). Addition of trehalose positively affected SLMs aerodynamic properties. The results of in vitro dissolution testing indicated that salbutamol sulfate release from the tested SLMs formulations was modified, in comparison to the raw drug release. In conclusion, SLMs in a form of DPIs were successfully developed and numerous factors that affects SLMs properties were identified in this study. Further research is required for full understanding of each factor's influence on SLMs properties and optimization of DPIs with maximized FPFs.",
publisher = "Elsevier B.V.",
journal = "European Journal of Pharmaceutical Sciences",
title = "Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery",
volume = "156",
doi = "10.1016/j.ejps.2020.105588"
}

Ignjatović, J., Đuriš, J., Cvijić, S., Dobričić, V., Montepietra, A., Lombardi, C., Ibrić, S.,& Rossi, A.. (2021). Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery. in European Journal of Pharmaceutical Sciences
Elsevier B.V.., 156.
https://doi.org/10.1016/j.ejps.2020.105588

Ignjatović J, Đuriš J, Cvijić S, Dobričić V, Montepietra A, Lombardi C, Ibrić S, Rossi A. Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery. in European Journal of Pharmaceutical Sciences. 2021;156.
doi:10.1016/j.ejps.2020.105588 .

Ignjatović, Jelisaveta, Đuriš, Jelena, Cvijić, Sandra, Dobričić, Vladimir, Montepietra, Agnese, Lombardi, Chiara, Ibrić, Svetlana, Rossi, Alessandra, "Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery" in European Journal of Pharmaceutical Sciences, 156 (2021),
https://doi.org/10.1016/j.ejps.2020.105588 . .

TY  - JOUR
AU  - Ignjatović, Jelisaveta
AU  - Đuriš, Jelena
AU  - Đuriš, Mihal
AU  - Bočarski, Teodora
AU  - Vasilijević, Vanja
AU  - Aleksić, Ivana
AU  - Cvijić, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3808
AB  - Hot-melt coating (HMC) is an alternative, solvent-free coating method generally used to modify substrate release rate and/or mask its unpleasant taste. The aim of this study was to assess two HMC methods (pan-coating and mortar-coating) by assaying functional properties of the coated  material.  The  selected  substrates  included  highly  soluble  sodium  chloride  (model substance) and caffeine (bitter drug), and the coating agent was glycerol distearate without/with the addition of liquid paraffin.  Experiments  with  sodium  chloride  revealed  that  pan-coating  yielded  particles  of  more regular  shape,  while  mortar-coating  yielded  samples  of  more  uniform  coating  layer.  The flowability of the coated material depended on the particle size. Sustained sodium chloride release was achieved for all mortar-coated and some pan-coated samples. The analysis of the results indicated mortar-coating as a preferable HMC method for caffeine coating. The resulting caffeine yield  in  the  coated  samples  was  high  (99%),  the  material  showed  satisfactory  mechanical properties and drug release from the coated particles was sustained. Overall, the obtained results suggest  that  both  pan-  and  mortar-coating  can  be  used  to  sustain  the  release  of  drugs  with unpleasant taste, but mortar-coating can be considered as a more simple and practical method that can be potentially used in compounding pharmacies.
AB  - Oblaganje topljenjem je alternativna metoda oblaganja, bez upotrebe rastvarača i uglavnom se koristi za modifikaciju brzine rastvaranja i/ili maskiranje neprijatnog ukusa supstrata. Cilj ovog rada je da se procene dve metode za oblaganje topljenjem (oblaganje u bubnju i oblaganje u pateni), ispitivanjem funkcionalnih karakteristika obloženog materijala. Izabrana su dva visoko rastvorljiva supstrata: natrijum-hlorid (model supstanca) i kofein (lekovita supstanca gorkog ukusa), a za oblaganje je korišćen glicerildistearat bez/sa dodatkom tečnog parafina. Eksperimenti sa natrijum-hloridom su pokazali da su oblaganjem u bubnju dobijene čestice pravilnijeg oblika, dok su oblaganjem u pateni dobijeni uzorci sa ujednačenijom oblogom. Protočnost obloženog materijala je zavisila od veličine čestica. Usporeno rastvaranje natrijumhlorida postignuto je kod svih uzoraka obloženih u pateni i kod nekih uzoraka obloženih u bubnju. Analiza rezultata je izdvojila oblaganje u pateni kao pogodniju metodu za oblaganje kofeina. Dobijeni prinos obloženih čestica kofeina je bio visok (99%), obloženi materijal je imao zadovoljavajuće mehaničke osobine i postignuta je usporena brzina rastvaranja kofeina. Sumarno, dobijeni rezultati su pokazali da se i oblaganje u bubnju i u pateni mogu koristiti za usporavanje rastvaranja lekovitih supstanci neprijatnog ukusa, no oblaganje u pateni predstavlja jednostavniju i praktičniju metodu koja se potencijalno može koristiti i u izradi magistralnih lekova.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Assessment of hot-melt coating methods for multiparticulate substrates: mortar-coating vs. pan-coating
T1  - Procena metoda za oblaganje višečestičnih supstrata topljenjem - oblaganje u pateni vs. oblaganje u bubnju
VL  - 71
IS  - 1
SP  - 35
EP  - 54
DO  - 10.5937/arhfarm71-30266
ER  - 

@article{
author = "Ignjatović, Jelisaveta and Đuriš, Jelena and Đuriš, Mihal and Bočarski, Teodora and Vasilijević, Vanja and Aleksić, Ivana and Cvijić, Sandra",
year = "2021",
abstract = "Hot-melt coating (HMC) is an alternative, solvent-free coating method generally used to modify substrate release rate and/or mask its unpleasant taste. The aim of this study was to assess two HMC methods (pan-coating and mortar-coating) by assaying functional properties of the coated  material.  The  selected  substrates  included  highly  soluble  sodium  chloride  (model substance) and caffeine (bitter drug), and the coating agent was glycerol distearate without/with the addition of liquid paraffin.  Experiments  with  sodium  chloride  revealed  that  pan-coating  yielded  particles  of  more regular  shape,  while  mortar-coating  yielded  samples  of  more  uniform  coating  layer.  The flowability of the coated material depended on the particle size. Sustained sodium chloride release was achieved for all mortar-coated and some pan-coated samples. The analysis of the results indicated mortar-coating as a preferable HMC method for caffeine coating. The resulting caffeine yield  in  the  coated  samples  was  high  (99%),  the  material  showed  satisfactory  mechanical properties and drug release from the coated particles was sustained. Overall, the obtained results suggest  that  both  pan-  and  mortar-coating  can  be  used  to  sustain  the  release  of  drugs  with unpleasant taste, but mortar-coating can be considered as a more simple and practical method that can be potentially used in compounding pharmacies., Oblaganje topljenjem je alternativna metoda oblaganja, bez upotrebe rastvarača i uglavnom se koristi za modifikaciju brzine rastvaranja i/ili maskiranje neprijatnog ukusa supstrata. Cilj ovog rada je da se procene dve metode za oblaganje topljenjem (oblaganje u bubnju i oblaganje u pateni), ispitivanjem funkcionalnih karakteristika obloženog materijala. Izabrana su dva visoko rastvorljiva supstrata: natrijum-hlorid (model supstanca) i kofein (lekovita supstanca gorkog ukusa), a za oblaganje je korišćen glicerildistearat bez/sa dodatkom tečnog parafina. Eksperimenti sa natrijum-hloridom su pokazali da su oblaganjem u bubnju dobijene čestice pravilnijeg oblika, dok su oblaganjem u pateni dobijeni uzorci sa ujednačenijom oblogom. Protočnost obloženog materijala je zavisila od veličine čestica. Usporeno rastvaranje natrijumhlorida postignuto je kod svih uzoraka obloženih u pateni i kod nekih uzoraka obloženih u bubnju. Analiza rezultata je izdvojila oblaganje u pateni kao pogodniju metodu za oblaganje kofeina. Dobijeni prinos obloženih čestica kofeina je bio visok (99%), obloženi materijal je imao zadovoljavajuće mehaničke osobine i postignuta je usporena brzina rastvaranja kofeina. Sumarno, dobijeni rezultati su pokazali da se i oblaganje u bubnju i u pateni mogu koristiti za usporavanje rastvaranja lekovitih supstanci neprijatnog ukusa, no oblaganje u pateni predstavlja jednostavniju i praktičniju metodu koja se potencijalno može koristiti i u izradi magistralnih lekova.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Assessment of hot-melt coating methods for multiparticulate substrates: mortar-coating vs. pan-coating, Procena metoda za oblaganje višečestičnih supstrata topljenjem - oblaganje u pateni vs. oblaganje u bubnju",
volume = "71",
number = "1",
pages = "35-54",
doi = "10.5937/arhfarm71-30266"
}

Ignjatović, J., Đuriš, J., Đuriš, M., Bočarski, T., Vasilijević, V., Aleksić, I.,& Cvijić, S.. (2021). Assessment of hot-melt coating methods for multiparticulate substrates: mortar-coating vs. pan-coating. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 71(1), 35-54.
https://doi.org/10.5937/arhfarm71-30266

Ignjatović J, Đuriš J, Đuriš M, Bočarski T, Vasilijević V, Aleksić I, Cvijić S. Assessment of hot-melt coating methods for multiparticulate substrates: mortar-coating vs. pan-coating. in Arhiv za farmaciju. 2021;71(1):35-54.
doi:10.5937/arhfarm71-30266 .

Ignjatović, Jelisaveta, Đuriš, Jelena, Đuriš, Mihal, Bočarski, Teodora, Vasilijević, Vanja, Aleksić, Ivana, Cvijić, Sandra, "Assessment of hot-melt coating methods for multiparticulate substrates: mortar-coating vs. pan-coating" in Arhiv za farmaciju, 71, no. 1 (2021):35-54,
https://doi.org/10.5937/arhfarm71-30266 . .

TY  - JOUR
AU  - Kurćubić, Ivana
AU  - Cvijić, Sandra
AU  - Filipčev, Bojana
AU  - Ignjatović, Jelisaveta
AU  - Ignjatović, Svetlana
AU  - Đuriš, Jelena
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3570
PB  - Elsevier
T2  - Reactive and Functional Polymers
T1  - Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling
VL  - 151
DO  - 10.1016/j.reactfunctpolym.2020.104587
ER  - 

@article{
author = "Kurćubić, Ivana and Cvijić, Sandra and Filipčev, Bojana and Ignjatović, Jelisaveta and Ignjatović, Svetlana and Đuriš, Jelena",
year = "2020",
publisher = "Elsevier",
journal = "Reactive and Functional Polymers",
title = "Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling",
volume = "151",
doi = "10.1016/j.reactfunctpolym.2020.104587"
}

Kurćubić, I., Cvijić, S., Filipčev, B., Ignjatović, J., Ignjatović, S.,& Đuriš, J.. (2020). Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling. in Reactive and Functional Polymers
Elsevier., 151.
https://doi.org/10.1016/j.reactfunctpolym.2020.104587

Kurćubić I, Cvijić S, Filipčev B, Ignjatović J, Ignjatović S, Đuriš J. Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling. in Reactive and Functional Polymers. 2020;151.
doi:10.1016/j.reactfunctpolym.2020.104587 .

Kurćubić, Ivana, Cvijić, Sandra, Filipčev, Bojana, Ignjatović, Jelisaveta, Ignjatović, Svetlana, Đuriš, Jelena, "Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling" in Reactive and Functional Polymers, 151 (2020),
https://doi.org/10.1016/j.reactfunctpolym.2020.104587 . .